Merus announced data from 43 evaluable patients who received the petosemtamab + Keytruda combination. Credit: Smart Calendar via Shutterstock. · Clinical Trials Arena · Smart Calendar via Shutterstock ...

On Wednesday, the FDA approved Merus N.V.’s (NASDAQ:MRUS) Bizengri (zenocutuzumab-zbco) as the first and only treatment indicated for adults with pancreatic adenocarcinoma or non–small cell lung ...

BMO Capital Markets maintained its Outperform rating on Merus N.V. (NASDAQ:MRUS) shares on May 24 while raising its price target from $96 to $110. The revision comes after encouraging Phase 2 data for ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Nasdaq provides company’s SEC filings, which are financial statements and reports filed electronically with the U.S. Securities and Exchange Commission (SEC) by Quotemedia. The SEC requires all ...

Merus’ NRG1 gene targeting cancer treatment helped to shrink tumors and kept working for up to 9.1 months, leaving the company’s leadership with an important question: partner up or go it alone for ...

Merus N.V. (NASDAQ:MRUS) stock moved lower on Monday. The company announced a research collaboration and license agreement with Biohaven Ltd. (NYSE:BHVN). Here’s what you need to know. What To Know: ...

Shares of Merus N.V. (MRUS) rocketed 32% on Friday morning after the stock witnessed price target hikes on the heels of the company announcing positive data from one of its ongoing drug trials.

A targeted cancer therapy from Merus has early clinical trial results suggesting it can treat tumors characterized by a genetic signature that hasn’t been addressed before, and the biotech is eying ...

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and mining exploration companies often lose money for years before finding success with ...

However, even though Dragon Ball Super has now seemingly taken Merus off of the game board, the character’s introduction seems too significant to be a simple one-off. Given everything we’ve learned ...

Merus presented pre-clinical data for its lead candidate, zenocutuzumab, and MCLA-158 at a scientific conference today. Impressive results among the first seven patients treated with MCLA-158 in a ...